BACKGROUND: Focal therapy is an emerging mini-invasive treatment modality for @entity263 aimed to reduce the morbidity associated with radical therapy while maintaining optimal @entity5 control. We report the mid-term oncological and functional results of @entity298 @entity2101 ( @entity2101 ) in a prospective cohort of @entity1 . METHODS: Over 8 years, hemiablation @entity2101 was primarily performed in 50 selected @entity1 with biopsy-proven clinically localized unilateral, low-intermediate risk @entity263 in complete concordance with the @entity263 lesions identified by magnetic resonance imaging with precise loci matching on multimodal approach. Post-treatment follow-up included regular serial PSA measurements. Biochemical recurrence was reported using Stuttgart and Phoenix criteria. The latter was used as a threshold to offer whole-gland biopsies. RESULTS: Complete follow-up was available for all @entity1 and the median follow-up was 39.5 months (range: 6-94). Mean nadir PSA value was 1.6   ng   ml(-1), which represents 72% reduction compared with initial PSA pre-treatment value (P<0.001). Median time to achieve PSA nadir was 3 months. Biochemical recurrence, according to Phoenix and Stuttgart definition, occurred in 28 and 36% of @entity1 , respectively. The 5-year actuarial metastases-free survival, @entity5 -specific survival and overall survival rates were 93, 100 and 87%, respectively. Out of the eight @entity1 undergoing biopsy, six @entity1 had a positive biopsy for @entity5 occurring in the untreated contralateral (n=3) or treated @entity3948 (n=1) or bilaterally (n=2). A Clavien-Dindo grade 3b complication occurred in two @entity1 . Complete continence (no pads) and erection sufficient for intercourse were documented in 94 or 80% of @entity1 , respectively. CONCLUSION: Hemiablation @entity2101 therapy, delivered with intention to treat, for carefully selected @entity1 affords mid-term promising functional and oncological outcomes. The effectiveness of this technique should be now compared with whole-gland radical therapy. @entity263 and @entity4623 advance online publication, 24 November 2015; doi:10.1038/pcan.2015.55.

A prospective clinical trial of XXXX for clinically @entity263 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'prostate cancer', 'Prostate Cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity3948 :: ('MESH:C538521', 'Disease') :: ['ipsilateral lobe'] @entity2101 :: ('MESH:C538394', 'Disease') :: ['high-intensity focused ultrasound', 'HIFU'] @entity4623 :: ('MESH:D011469', 'Disease') :: ['Prostatic Diseases'] @entity298 :: ('MESH:D010538', 'Disease') :: ['primary hemiablation']
@entity2101 :: (MESH:C538394,Disease) :: ['HIFU hemiablation']
